Introduction: Few studies have investigated the long-term effects of a maintenance regimen in the prevention of relapses in scalp seborrheic dermatitis (SD), in particular following biomarker changes. Materials and methods: A new shampoo
containing beta-glycyrrhetinic acid (18bGA) in addition to cyclopiroxolamine (CPO) and zinc pyrithione (ZP) was tested in 67 subjects suffering from SD with moderate to severe erythema and itching in a biphasic study. After a first common intensive treatment phase (investigational product thrice a week 9 2 weeks), subjects randomly received the investigational product once a Electronic supplementary material The online version of this article (doi:10.1007/s13555-014-0047-0) contains supplementary material, which is available to authorized users.
INTRODUCTION
Seborrheic dermatitis (SD) is a chronic dermatosis occurring in about 3-5% of the adult population [1] [2] [3] , characterized by dandruff, pruritus and, in some cases, mild to marked erythema, and affecting sebum-rich areas such as the scalp. The pathogenesis of SD is complex and appears to result from pathophysiological interactions between scalp skin, cutaneous microflora, and the cutaneous immune system in the stratum corneum (SC) [4] .
In particular, Malassezia yeasts, commonly found as part of the normal skin flora [5, 6] but present in higher proportions in the scalp skin of patients with SD, were shown to trigger inflammatory and hyperproliferative epidermal responses with incomplete corneocyte differentiation, leading to an impaired SC barrier [4] . Malassezia species (M. restricta and M. globosa) appear to be the most frequently involved [7] [8] [9] . In addition, several biomarkers were shown to be modified in SD and restored by therapeutic intervention, and can be studied by non-invasive sampling: inflammation, hyperproliferation, and skin barrier function [6, 10] .
Treatment of SD has recently focused on controlling inflammation and reducing the number of Malassezia yeasts. Treatments combining keratolytic agents or topical corticosteroids and antifungals have proven their efficacy [11] [12] [13] . The combination of ciclopiroxolamine (CPO) and zinc pyrithione (ZP) has recently been proposed, based on the potentially complementary effect of the two compounds. CPO is a broad-spectrum antifungal with an anti-inflammatory activity by inhibition of prostaglandin and leukotriene synthesis [14, 15] . ZP has both non-specific keratolytic and antifungal activity [16, 17] and can normalize the impaired SC ultrastructure observed in SD [18, 19] . A 1.5% CPO/1% ZP shampoo displayed a synergistic inhibitory and fungicidal effect on two species of Malassezia (M. globosa and M. restricta) in vitro with greater efficacy than 2% ketoconazole [20] , and highly significantly reduced the extent and severity of scaling, as well as erythema and pruritus, as shown by a randomized clinical study with blinded investigators [21] . Recently, 18b-glycyrrhetinic acid (18bGA) isolated from licorice root was shown to reduce tumor necrosis factor (TNF)-a production and nuclear factor kappa-light-chainenhancer of activated B cells (NF-jB) activation based on mammalian polymerase inhibition tests and in vivo experiments in a mouse model [22] , as well as the expression of pro-inflammatory genes through the inhibition of NF-jB and phosphoinositide 3-kinase (PI3K) activity [23] . On the basis of these results, 18bGA has been suggested as a potential treatment of inflammatory-mediated diseases [23] .
On the grounds of the proven individual effect of CPO/ZP and 18bGA, a shampoo containing these three compounds might therefore be of value in the short-term and long-term treatment of SD. The purpose of this study was therefore to assess the antidandruff, antifungal and antiinflammatory effect of short-term intensive treatment with such a shampoo, the persistence of the effect, and the value of maintenance treatment in the prevention of recurrences. The correlation between clinical dandruff score and Malassezia load was also determined in order to objectively support the usefulness of maintenance therapy with this investigational product.
METHODS

Study Design
This 
Patient Population
Inclusion Criteria
Female or male patients aged between 18 and 60 years, inclusive, with clinically diagnosed scalp SD including scaling, erythema and pruritus, and an overall clinical score assessed by the investigator as C20 (according to the method of Squire and Goode [11] , with an intensity C2 on at least one of the four scalp areas) were recruited by French and Portuguese dermatologists. At least one other episode of scaling (with erythema and itching) described by the subject had occurred within 6 months before inclusion.
Exclusion Criteria
Patients with the following criteria were not included: pregnancy or breastfeeding, history of allergy to any of the ingredients of the test product (e.g., CPO, ZP, keluamid, 18bGA, etc.) or of hygiene or hair care products, chronic or acute progressive disease liable to interfere with the results of the study, dermatological condition or progressive skin lesion of the scalp, SD requiring concomitant topical corticosteroid treatment.
Systemic treatment (cardiovascular, endocrine, or anti-inflammatory drugs, corticosteroids, antibiotics, antidepressants, antipsychotics, antineoplastics, immunosuppressants), or topical treatments applied to the scalp within 7 days before inclusion in the study and that could interfere with the results of the study, any product applied to the scalp that was potentially effective on scaling conditions or that could limit the effectiveness of the study product within 2 weeks before inclusion:
anti-inflammatory drugs, ketoconazole, antidandruff shampoo, antifungal, vinegar rinse, essential oils, etc., were other reasons for exclusion, as were dying, bleaching, perming, smoothing and/or straightening within 2 weeks before inclusion.
Study Products, Randomization and Blinding
The investigational product was an antidandruff shampoo (Kelual DS Ò , DUCRAY Dermatological Laboratories, Boulogne Billancourt, France) containing CPO, ZP and 18bGA and a washing base, while the ''control'' product was a neutral shampoo (Extra Doux Ò , Ducray laboratories). Both test and control shampoos were provided by Pierre Fabre Dermo-Cosmétique laboratories. Each use of the investigational product consisted of two applications with a 3-min exposure time each before rinsing. The two products were labeled and numbered according to a computergenerated randomization list established by Pierre Fabre Biometrie and were allocated to each patient according to their order of inclusion.
The study was open-label because the patients could easily differentiate between the test products by virtue of their very different smell, viscosity and color.
Treatment Schedule
The study took place over 10 weeks, including a 2-week intensive treatment phase and an 8-week maintenance phase. On the day of inclusion (W0), all patients received the investigational product for use thrice a week 9 2 weeks (i.e., six times during the intensive treatment phase), and the last use had to take place 2 days before visits so that the interval since using the shampoo was about 2 days (± day). Patients could use neutral shampoo between two treatments if they were used to shampooing more than thrice a week, but still observing the interval of 2 days without the use of any shampoo before visits. At the beginning of the maintenance phase (W2), patients were randomly allocated either to continue the treatment with the investigational product once a week and the neutral shampoo additionally in order to achieve the usual shampooing frequency (maintenance group), or to use the neutral shampoo only at their usual frequency (control group) for an additional 8 weeks. This protocol left some degree of freedom to patients in order to encourage compliance. Any treatment liable to interfere with the evaluation of the study outcome, such as permanent waves and coloring, shampoos not provided in the study, systemic or topical treatments with antibiotics, antifungals, corticosteroids or retinoids, or any topical treatment for SD or dandruff, was strictly forbidden for the whole of the study.
Study Plan
At each visit, i.e., at inclusion (W0), after week 1 (W1) and 2 (W2) of the intensive treatment phase, and after week 4 (W6) and 8 (W10) of the maintenance phase, the investigator performed a scalp examination and swab sampling on welldefined lesional areas for biochemical and microbiological evaluations, scored clinical parameters (dandruff, erythema), and assessed treatment global efficacy. In the meantime, patients self-assessed global efficacy and their scaling condition (i.e., dandruff, itching, discomfort) using questionnaires.
Study Endpoints
Primary Endpoint
The main efficacy endpoint was the antifungal action assessed by measuring the change in M. 
Secondary Endpoints
To evaluate the persistence of intensive treatment and the value of maintenance therapy for 8 weeks after the end of the intensive treatment phase, several clinical parameters and biochemical and microbiological cutaneous markers of SD were used as secondary endpoints.
Clinical Endpoints
• Change in overall clinical dandruff score, graded by the investigator, at W1, W2, W6
and W10 compared with W0. The overall clinical dandruff score, ranging from 0 to 80, was calculated taking into account the area covered by SD lesions and their severity, as described by Squire and Goode [11] .
• Change in irritation symptoms from W0 at each visit by rating erythema on a 4-point, semi-quantitative scale: • Time to first recurrence (when condition C baseline score) for at least one of the three items: dandruff, discomfort or itching.
• Compliance (number of uses of the investigational product reported by the subject compared with the theoretical number).
Biochemical and Microbiological Cutaneous Markers of SD
The change in M. restricta and globosa populations at W1, W6 and W10 from W0 was assessed by PCR measurements. Informed consent was obtained from all patients before being included in the study.
RESULTS
Study Population
A total of 67 patients (27 in Fig. 1 .
Secondary Endpoint
Microbiological Markers
A highly significant drop in log Malassezia restricta and globosa was observed after 1 week of treatment, i.e., three applications (p\0.0001 for all measurements, Fig. 1 ). Subsequently, compared with the end of the intensive treatment phase (W2), log Malassezia increased throughout the maintenance phase in each group. However, whereas this increase was highly significant in the control group at W6 and W10 (p\0.0001 for log M. restricta and globosa), it was only significant for log M. globosa at W10 (p\0.01) in the treated group ( Fig. 1 ). During the maintenance phase, in the control group there was a return to baseline levels at W10 for log M. restricta and W6 and W10 for log M. globosa (p[0.05 versus W0).
Noticeably, a highly significant difference was observed between the two groups at each time point (p\0.0001), Malassezia spp. levels being significantly higher in the control group than in the treated group (Fig. 1) .
Clinical Evaluation
A clinical improvement was observed during the study, with a highly significant decrease in overall clinical dandruff score during the intensive treatment phase and a non-return to baseline conditions in the two groups at W6 and W10, the intergroup difference being highly significant at each time point in favor of the treated group (p\0.0001 for the difference in changes at W6 and W10 vs. W2) ( Table 2) .
A highly significant decrease in clinical score for erythema at W1 and W2 reflected a rapid improvement in irritation during the intensive treatment phase ( Fig. 2a) , which was maintained at W10 in the treated group (p\0.0001 versus W0) but returned to baseline in the control group (p[0.05).
The subjective global efficacy (SGA) score assessed by investigator and subject increased during the intensive treatment phase and was maintained (i.e., non-return to baseline in the two groups), especially in the treated group: an investigator-assessed cumulative improvement (i.e., slight and significant improvement and complete recovery) was found in 97% of cases at W2, and in 76% in the treated group versus 27% in the control group at W10 (Fig. 2b) . Likewise, a subject-assessed cumulative improvement was found in 94% of cases at W2, and in 70% in the treated group versus 20% in the control group at W10.
Self-assessment of scaling, discomfort and itching by patients revealed a sustained improvement at W10 versus W0 in the treated group compared with a return to baseline in the control group for dandruff (p\0.0001 and p[0.05 at W10 versus W0 in the treated and control groups, respectively) and discomfort (p\0.0001 and p[0.05, respectively), whereas itching continued to be improved in both groups (p\0.0001 and p\0.05, respectively) ( Fig. 2c-e ). As regards the changes between W0 and W10, the intergroup difference was significant or very significant for discomfort, dandruff, and itching.
Very good compliance was observed, with a significant negative correlation with the M. restricta population during the first week of the intensive treatment phase (which decreased when compliance increased, r = -0.41439, p\0.001). Time to first recurrence was studied as a survival analysis, as illustrated in Fig. 3 , and a log-rank test (Chi squared) showed a statistically significant difference between the two groups in favor of the treated group (p\0.0001). 
Biochemical Markers
At the end of the intensive treatment phase, the levels of inflammation and pruritus markers decreased significantly: cathepsin S by -70% (p\0.0001), histamine by approximately -65% (p\0.0001) ( Fig. 4 ) and IL-8 by -87.5%
(p\0.05). The IL-1RA/IL-1a ratio decreased by about -20% (p\0.05), reflecting an antiinflammatory process. The cell cohesion marker PLK decreased significantly (-41.7%, p\0.01) ( Table 3) .
During the maintenance phase, the treatment effect regressed significantly in the control group (Table 3 ) for all markers. In the treated group, the decrease was only reversed in the case of histamine levels, which reverted to the initial state at the end of the maintenance phase and was not statistically different from the control group at W10. Levels of other markers remained unchanged (cathepsin S, IL-8) or declined slightly in the treated group, especially for IL-1RA/IL-1a, with a significant difference at W10 versus W0 and W2 (p\0.005 and p\0.05, respectively). There was a significant difference between the two groups for the changes from baseline in IL-8 (p\0.05) and IL-1RA/IL-1a ratio (p\0.05) in favor of the treated group, with a significantly greater regression of the treatment effect in the control.
PLK levels continued to decline in the treated group (-18.2%, p[0.05 versus W2), Fig. 2 a-e Evolution of clinical criteria during the intensive treatment phase (W0 to W2) in the global study population and during the maintenance phase (W2 to W10) in control and treated patients (a erythema, b global efficacy, c self-assessment of scaling, d selfassessment of discomfort, e self-assessment of itching). For the intensive treatment phase, a paired Student's t test or a Wilcoxon's signed rank test, depending on normality of distributions, was used on changes between W0 and W1 and W2, respectively. For the maintenance phase, a Wilcoxon's signed rank test was used on changes between W2 and W6 and W10, respectively. *p\0.05, **p\0.01, ***p\0.001, ****p\0.0001, in blue: intragroup versus W0, in red: intergroup W10/W0
reflecting an improvement in scaling, whereas it significantly increased in the control group (?4.2%, p\0.005) to reach a non-statistically different level at W10 versus baseline.
Intergroup comparison showed a significant difference in the time course of PLK during the maintenance phase in favor of the treated group (p\0.01), revealing a maintenance effect in the treated group only. Table 4a -c, the overall clinical score was positively correlated with histamine and log M. restricta (Table 4a) , log M. globosa in the treated group (Table 4c ) and IL-1RA/IL1a in the control group (Table 4c) , and during the intensive treatment phase (Table 4b) .
Correlations
As shown in
Erythema was positively correlated with IL-1RA/IL-1a, histamine and PLK in the treated group (Table 4a) .
Itching was positively correlated with IL-1RA/IL-1a and log M. total in the control group (Table 4c) , while global efficacy was negatively correlated with histamine in the treated group (Table 4a , c), IL-1RA/IL-1a (Table 4b) , and log M. total in the control group (Table 4a) .
Safety
Twenty-seven adverse events unrelated to the study drug, including one pregnancy (which led to early study termination), and 23 adverse events suspected of being related to the investigational product were identified. These were mainly transient side effects of low to mild severity, such as stinging, itching, and burning sensations, and resolved spontaneously within 1 week without any particular action, resulting in a decrease in the percentage of 'good' tolerance (27%, 5%, 3% and 3% at week 1, 2, 6 and 10, respectively, in the maintenance group), and an increase in the percentage of 'very good' tolerance with time (73%, 95%, 97% and 97% at week 1, 2, 6 and 10, respectively, in the maintenance group). results for scaling, including global dandruff score, self-assessment of dandruff). It should be noted that in this study, the intensive treatment phase was half as long as the standard intensive treatments, which usually last 4 weeks [25] ). It is notable that effects were measured from the first application, which is of considerable interest to patients eager to be relieved of their symptoms and which might contribute to good compliance. This study was conducted during the winter, when the disease is more frequent but also when the symptoms are milder, requiring a much larger sample size to demonstrate a real treatment effect by the study product [26] . In our study, an effect was demonstrated despite a relatively small sample size (n = 33 and n = 34 for the treated and control groups, respectively). This effect declined after the discontinuation of treatment in the control group, but for some parameters a complete return to baseline was not observed, from which it may be concluded that some improvements persisted for 8 weeks after stopping treatment: overall clinical Other improvements were amplified, e.g., overall clinical dandruff score and IL-1RA/IL-1a ratio, whereas only one factor returned to baseline: histamine level.
A positive relationship was found between the main clinical signs of SD (dandruff, itching, and erythema) and the following biomarkers:
Malassezia populations, histamine level, and IL-1RA/IL-1a ratio. The overall efficacy was negatively correlated with these biomarkers. In the case of cathepsin S, its levels decreased markedly at the end of the intensive treatment phase (by 70%, p\0.0001). Levels of cathepsin S, an activator of proteinase-activated receptor-2 (PAR2) [27] , were recently shown to be increased, along with PAR2 and histamine, in subjects with SD, and to be correlated with clinical parameters linked to the severity of SD and itching, suggesting that cathepsin S could be used as a biomarker of pruritus. Biomarkers of pruritus These new methods of biomolecular analysis allow a more comprehensive and objective evaluation of improvements during treatment.
So far, only a few recent studies have evaluated SD treatment by criteria other than clinical and microbiological [10, 19, 24] . Mills et al. [19] performed a systematic study of the transcriptome of biopsies of SD scalp lesions.
They showed that SD was characterized by a diminished expression of genes involved in lipid metabolism and an increased expression of genes involved in inflammation and that, under conditions in which symptoms resolved, ZP produced a transcriptomic profile similar to healthy skin. However, this method of analysis cannot be easily applied in large-scale clinical studies.
A non-invasive skin surface sampling methodology combined with highly sensitive ELISA-based quantification was developed in 2001 [29] , permitting larger clinical sample sizes. This methodology was applied to differentiate SD from normal subjects and showed a link between classical criteria of SD evaluation and IL-1RA (ratio to IL-1a), IL-2, IFNc, nitric oxide and TNF-a [30] . Recently, Kerr et al. [24] compared normal and SD subjects before and after a 3-week treatment with a ZPcontaining shampoo and showed an association between the subjective perception of itch in the scalp and histamine level in the SC, both before and after treatment. Kerr et al. [10] further investigated a set of biomarkers in subjects with dandruff treated for 3 weeks with a commercial ZP shampoo versus a control. They showed that the resolution of flaking with treatment was associated with a reduction in Based on the inflammatory component of SD, the lack of synchronization between proliferation and differentiation, and the impaired barrier function, Schwartz et al.
suggested that SD could belong to the group of inflammatory dermatoses, including psoriasis, atopic dermatitis and acne, although these conditions differ in their triggering events [4] . Accordingly, the addition of 18bGA, shown to exert an anti-inflammatory action in cultured cells [22, 23] and in a model of acute inflammation in the mouse ear [22] , could contribute to the in vivo anti-inflammatory action observed in our study, in combination with CPO and ZP.
In conclusion, the effectiveness of this investigational product on the maintenance phase of SD was clearly and objectively demonstrated at the clinical, biochemical and microbiological levels: the decrease in biomarkers and symptoms of SD persisted at 10 weeks in the treated group. In line with FDA recommendations encouraging the use of biomarkers [31] , the correlations observed in our study between clinical signs and biomarkers provide clues to explain the resolution of SD at the molecular level and confirm the value of biomolecular endpoints for the detailed assessment of SD treatment. The fact that our methodology allows biomarkers to be studied through non-invasive sampling is particularly relevant on both practical and ethical grounds.
Furthermore, the convergence of conventional clinical measurements and objective measurements strongly demonstrates the usefulness of maintenance therapy. 
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